Sign in

CIK 0001815442

  • Large accelerated filer

Kymera Therapeutics, Inc.

Sign in to watch
Ticker
KYMR
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
812992166
Phone
+1 857-285-5314
Business address
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA, 02472
Former names
Kymera Therapeutics, Inc.
  1. 4 Derivatives Options or other derivatives
  2. 4 Derivatives Options or other derivatives
  3. 4 Derivatives Options or other derivatives
  4. 4 Derivatives Options or other derivatives
  5. 4 Planned sale Director sold 31,798 shares at an average $103.75 ($3,299,037)
  6. 4 Planned sale Director sold 478,198 shares at an average $94.72 ($45,293,294)
  7. 4 Planned sale Chief Business Officer sold 2,500 shares at $99.00 ($247,500)
  8. 4 Exercise or conversion Chief Financial Officer acquired 12,653 shares (option exercise)
  9. 4 Planned sale Chief Operating Officer sold 17,184 shares at an average $79.92 ($1,373,290)
  10. 4 Exercise or conversion Director acquired 1,000 shares (option exercise)
  11. 4 Exercise or conversion Chief Financial Officer acquired 15,000 shares (option exercise)
  12. 4 Planned sale Director sold 3,000 shares at $87.00 ($261,000)
  13. 4 Planned sale Chief Executive Officer sold 30,000 shares at an average $81.18 ($2,435,377)
  14. 4 Planned sale Director sold 6,000 shares at an average $89.96 ($539,772)
  15. 4 Planned sale Chief Operating Officer sold 300 shares at $90.00 ($27,000)
  16. 4 Planned sale Chief Business Officer sold 1,347 shares at $90.00 ($121,230)
  17. 4 Planned sale Chief Operating Officer sold 6,551 shares at an average $90.00 ($589,598)
  18. 4 Planned sale Director sold 9,494 shares at an average $90.01 ($854,539)
  19. 4 Planned sale Chief Business Officer sold 10,264 shares at an average $87.47 ($897,782)
  20. 4 Planned sale Director sold 12,000 shares at an average $85.39 ($1,024,660)

Page 2 of 15 · 296 filings